Table of Contents
In January 2026, the FDA accepted Compass Pathways’ Investigational New Drug Application to study its synthetic psilocybin compound, COMP360, as a possible therapy for PTSD. A separate randomized controlled trial at Johns Hopkins has also recently completed. Both are early-stage investigations, and no treatment has been approved.
- A late-stage trial is now authorized. The FDA’s acceptance of Compass Pathways’ IND application clears the path for a multicenter, randomized, double-blind study of COMP360 in people with PTSD, a condition for which psilocybin has rarely been formally studied.
- Hopkins researchers report early encouraging signals. Dr. Sandeep Nayak described the results from a recently completed Johns Hopkins randomized controlled trial as ‘very good’ and ‘safe,’ while noting that a second dose did not appear to add clear benefit, a finding that is now informing a follow-on study.
- The Compass trial takes a different approach than most psychedelic research. Unlike many psilocybin studies, the COMP360 PTSD program does not include a focus on psychological support or psychedelic-assisted therapy as a component of the intervention.
- State-level policy is moving in parallel. Michigan, Massachusetts, and New Jersey have each introduced or advanced distinct legislative approaches, ranging from targeted decriminalization for PTSD diagnoses to broader therapeutic access frameworks and pilot medicalization programs.
- Model
- human
- Sample
- PTSD-diagnosed participants; exact N not yet reported for the Compass trial
- Dose
- COMP360 (synthetic psilocybin); dose not specified in the source
- Design
- Multicenter, randomized, double-blind, controlled study with open-label extension (Compass); separate completed randomized controlled trial at Johns Hopkins (NCT06407635)
- Key outcome
- Efficacy, safety, and tolerability of COMP360 in PTSD (primary endpoint not yet reported); Hopkins team reports preliminary safety and tolerability signals
- Main limitation
- No efficacy data from either trial have been publicly released; the Compass late-stage trial has not yet begun enrolling
What the Research Examined
On January 7, 2026, the U.S. Food and Drug Administration accepted Compass Pathways’ Investigational New Drug Application to study COMP360, its synthetic psilocybin formulation, as a possible therapy for post-traumatic stress disorder. COMP360 already holds FDA Breakthrough Therapy Designation for treatment-resistant depression, granted in 2018. The PTSD program marks an expansion into a condition where psilocybin has received little formal clinical scrutiny. Compass is partnering with Radial Health, an organization building a national clinic network, to help design outpatient delivery protocols ahead of any potential approval.
The planned Compass trial will be a multicenter, randomized, double-blind, controlled study with an open-label extension, assessing efficacy, safety, and tolerability. A notable feature is its departure from the psychedelic-assisted therapy model: the trial will not center psychological support as a core component, distinguishing it from most other psilocybin research. Separately, Johns Hopkins University recently completed a randomized controlled trial (ClinicalTrials.gov identifier NCT06407635) evaluating two doses of psilocybin with psychological support for PTSD. Dr. Sandeep Nayak, Assistant Professor at Hopkins, described preliminary results as encouraging and noted that a second dose did not appear to add clear benefit, a finding that is informing a new study he is designing.
These clinical developments sit inside a rapidly shifting policy environment. For readers tracking the evolving legal landscape for psilocybin therapy, the picture is one of parallel momentum: federal research authorization on one track, and state decriminalization and medicalization bills on another, each moving at its own pace and with its own scope.
What the Findings Show
- FDA IND Acceptance.The FDA accepted Compass Pathways’ IND application for COMP360 in PTSD on January 7, 2026, authorizing the initiation of a late-stage clinical trial.
- Hopkins Preliminary Signal.Dr. Nayak described early results from the completed Johns Hopkins randomized controlled trial as ‘very good’ and appearing safe, though no formal efficacy data have been published.
- Second-Dose Finding.In the Hopkins trial, a second dose of psilocybin did not show a clear added benefit over the first, prompting the team to design a new study comparing a single psilocybin dose to a single MDMA dose.
- Legislative Activity.Michigan House Bill 4686, Massachusetts House Bills 2532 and 2506, and New Jersey Senate Bill 2283 each represent distinct state-level approaches, from PTSD-specific decriminalization to pilot medicalization programs, advancing in parallel with federal research.
It is worth holding the clinical and legislative threads separately. The FDA’s IND acceptance is a procedural authorization to begin studying COMP360, not an approval of the compound as a treatment. No efficacy data from either the Compass or Hopkins PTSD trials have been publicly reported. The state bills, meanwhile, reflect advocacy and political momentum shaped partly by the existing depression and anxiety data for psilocybin, rather than by PTSD-specific trial results, which remain largely unpublished.
Is psilocybin being studied as a treatment for PTSD in clinical trials?
Yes. As of January 2026, Compass Pathways has received FDA clearance to begin a late-stage randomized controlled trial of its synthetic psilocybin compound, COMP360, for PTSD. Johns Hopkins also recently completed a separate randomized controlled trial. Neither trial has released full efficacy results, and no psilocybin treatment for PTSD has been approved.
What This Is, and What It Is Not
This is This recap covers a news article summarizing a regulatory development, two clinical trial programs in early-to-late-stage status, and several state legislative initiatives, none of which have produced published peer-reviewed efficacy data for psilocybin in PTSD.
This is not This is not a peer-reviewed clinical study, and it does not establish that psilocybin treats or cures PTSD. Nothing here constitutes medical advice. Individuals should consult a qualified healthcare provider about their own mental health care.
Our Take
There is something worth sitting with in the gap between legislative momentum and clinical evidence. Bills are being written, IND applications are being filed, and clinics are being designed, all before the efficacy data have arrived. That is not necessarily a failure of the process; it reflects how much people are suffering with PTSD, and how little the existing toolkit has offered them. Within the Church, we understand that the sacramental relationship with psilocybin does not wait on a pharmaceutical approval. But we also believe that rigorous science, honestly reported, is itself a form of reverence for what these medicines can do. Watching the Hopkins team ask careful questions about dose, sequence, and comparators feels like the right kind of humility before a profound compound.
If this emerging territory around psilocybin and trauma is drawing your attention, you are not alone in that pull. Whether you are a veteran, a clinician, a policy advocate, or simply someone carrying your own history, the questions being asked in these trials and these statehouses are ultimately about what it means to heal. We invite you to explore the resources here, stay grounded in what the evidence actually shows, and join a community that holds both the science and the spiritual dimension with care. The path forward is long, and it is worth walking slowly and honestly.
Frequently Asked Questions
What is the COMP360 compound being tested for PTSD?
COMP360 is a synthetic formulation of psilocybin developed by Compass Pathways. It already has FDA Breakthrough Therapy Designation for treatment-resistant depression and is now authorized for a late-stage randomized controlled trial in people with PTSD, following FDA acceptance of an Investigational New Drug Application in January 2026.
How does the Compass Pathways PTSD trial differ from other psilocybin studies?
Unlike most psilocybin clinical trials, the Compass PTSD study does not include psychological support or psychedelic-assisted therapy as a core component. It is designed as a multicenter, randomized, double-blind, controlled trial focused on efficacy, safety, and tolerability of the compound itself.
What did the Johns Hopkins psilocybin PTSD trial find?
Preliminary results described by Dr. Sandeep Nayak were characterized as very good and appearing safe. The trial also found no clear added benefit from a second dose of psilocybin, which is now informing a new study. Full peer-reviewed data have not yet been published.
Which states are considering psilocybin decriminalization or legalization for PTSD?
As of early 2026, Michigan introduced a bill to decriminalize psilocybin specifically for people with a PTSD diagnosis. Massachusetts advanced bills creating a therapeutic access framework and a pathway for veterans and qualifying patients. New Jersey introduced a pilot medicalization program tied to FDA guidelines.
Why is research on psilocybin for PTSD gaining momentum now?
Several factors are driving interest: the FDA’s 2024 rejection of MDMA-assisted therapy from Lykos Therapeutics left a gap in the PTSD pipeline, existing psilocybin data in depression and anxiety are considered promising, and the high prevalence of PTSD, especially among veterans, creates strong advocacy pressure for new treatment options.
Get the Mycelium Report
We read the new psilocybin and mushroom research so you do not have to. One honest, jargon-free dispatch, delivered daily. Free to join.
May love guide the hearts of all beings.
